Literature DB >> 22640442

Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews.

M J van der Werf1, M W Langendam, A Sandgren, D Manissero.   

Abstract

BACKGROUND: Existing international guidelines provide different recommendations for the management of contacts of multidrug-resistant tuberculosis (MDR-TB) patients.
OBJECTIVE: To conduct two systematic reviews with the aim of identifying chemoprophylactic approaches that are effective in contacts of MDR-TB patients to assist in policy making.
DESIGN: We systematically searched the Medline, Embase, Central, LILACS, TRIP and BIOSIS Preview databases for studies on the effectiveness of anti-tuberculosis drugs in preventing active TB in persons at risk of developing MDR-TB. This was done as an update of a systematic review from 2006 using the same methodology. In addition, we searched for studies including persons at risk of developing TB after exposure to non-MDR-TB patients who were treated with anti-tuberculosis drugs other than isoniazid or rifampicin.
RESULTS: Of 1195 references assessed in the update, one additional study could be included. As the initial review included two studies, the total number of included studies equals three. One study reported no contacts who developed TB, whether or not they received prophylaxis. The other two studies showed non-significant risk differences of 4% (95%CI -3 to 12), and 5% (95%CI -2 to 11), both in favour of chemoprophylaxis. For the additional review, 2480 references were assessed, but none could be included.
CONCLUSION: The attention given to MDR-TB in recent years has not resulted in publications on preventive treatment for contacts of MDR-TB patients. The available evidence is not sufficient to support or reject preventive treatment. Furthermore, the combined available evidence is of very low quality.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22640442     DOI: 10.5588/ijtld.11.0437

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  21 in total

1.  Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs.

Authors:  R Diel; N Lampenius
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

2.  Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study.

Authors:  Nishi Suryavanshi; Matthew Murrill; Amita Gupta; Michael Hughes; Anneke Hesseling; Soyeon Kim; Linda Naini; Lynne Jones; Betsy Smith; Nikhil Gupte; Rodney Dawson; Vidya Mave; Sushant Meshram; Alberto Mendoza-Ticona; Jorge Sanchez; Nagalingeswaran Kumarasamy; Kyla Comins; Francesca Conradie; Justin Shenje; Sandy Nerette Fontain; Anthony Garcia-Prats; Aida Asmelash; Supalert Nedsuwan; Lerato Mohapi; Umesh Lalloo; Ana Cristina Garcia Ferreira; Elisha Okeyo; Susan Swindells; Gavin Churchyard; N Sarita Shah
Journal:  Clin Infect Dis       Date:  2020-01-16       Impact factor: 9.079

Review 3.  Isoniazid-resistant tuberculosis in children: a systematic review.

Authors:  Courtney M Yuen; Arielle W Tolman; Ted Cohen; Jonathan B Parr; Salmaan Keshavjee; Mercedes C Becerra
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

4.  Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis.

Authors:  Jean-Philippe Lanoix; Fabrice Betoudji; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

5.  Commentary: a targets framework: dismantling the invisibility trap for children with drug-resistant tuberculosis.

Authors:  Mercedes C Becerra; Soumya Swaminathan
Journal:  J Public Health Policy       Date:  2014-09-11       Impact factor: 2.222

6.  Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.

Authors:  S Bamrah; R Brostrom; F Dorina; L Setik; R Song; L M Kawamura; A Heetderks; S Mase
Journal:  Int J Tuberc Lung Dis       Date:  2014-08       Impact factor: 2.373

Review 7.  Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.

Authors:  Suzanne M Marks; Sundari R Mase; Sapna Bamrah Morris
Journal:  Clin Infect Dis       Date:  2017-06-15       Impact factor: 9.079

8.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

9.  Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review.

Authors:  Miranda W Langendam; Edine W Tiemersma; Marieke J van der Werf; Andreas Sandgren
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

10.  Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays.

Authors:  A Bedini; E Garlassi; C Stentarelli; S Petrella; M Meacci; B Meccugni; M Meschiari; E Franceschini; S Cerri; A Brasacchio; F Rumpianesi; L Richeldi; C Mussini
Journal:  New Microbes New Infect       Date:  2016-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.